Switch theme
Sign up to access all valuation multiples
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is a Turkey-based company that operates in the drug business. It is mainly involved in the manufacturing of pharmaceuticals, veterinary drugs, and personal care products. Further, the group is also engaged in real estate development and leasing commercial property activities. Geographically, all the activities are carried out through the region of Turkey.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eczacıbaşı has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Eczacıbaşı achieved revenue of $231M and an EBITDA of $84.1M.
Eczacıbaşı expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eczacıbaşı valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $170M | $231M | XXX | XXX | XXX |
| Gross Profit | $17.5M | $57.5M | XXX | XXX | XXX |
| Gross Margin | 10% | 25% | XXX | XXX | XXX |
| EBITDA | $117M | $84.1M | XXX | XXX | XXX |
| EBITDA Margin | 69% | 36% | XXX | XXX | XXX |
| Net Profit | $110M | $72.1M | XXX | XXX | XXX |
| Net Margin | 64% | 31% | XXX | XXX | XXX |
| Net Debt | $35.3M | $25.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Eczacıbaşı's stock price is TRY 44 (or $1).
Eczacıbaşı has current market cap of TRY 30.1B (or $792M), and EV of TRY 30.6B (or $806M).
See Eczacıbaşı trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $806M | $792M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Eczacıbaşı has market cap of $792M and EV of $806M.
Eczacıbaşı's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Eczacıbaşı's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Eczacıbaşı and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $806M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 9.6x | XXX | XXX | XXX |
| P/E | 29.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 19.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEczacıbaşı's NTM/LTM revenue growth is n/a
Eczacıbaşı's revenue per employee for the last fiscal year averaged $16.5M, while opex per employee averaged $5.7M for the same period.
Over next 12 months, Eczacıbaşı's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Eczacıbaşı's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Eczacıbaşı and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 35% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -28% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $16.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $5.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 35% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eczacıbaşı acquired XXX companies to date.
Last acquisition by Eczacıbaşı was XXXXXXXX, XXXXX XXXXX XXXXXX . Eczacıbaşı acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Eczacıbaşı founded? | Eczacıbaşı was founded in 1951. |
| Where is Eczacıbaşı headquartered? | Eczacıbaşı is headquartered in Turkey. |
| How many employees does Eczacıbaşı have? | As of today, Eczacıbaşı has 14 employees. |
| Is Eczacıbaşı publicy listed? | Yes, Eczacıbaşı is a public company listed on IST. |
| What is the stock symbol of Eczacıbaşı? | Eczacıbaşı trades under ECILC ticker. |
| When did Eczacıbaşı go public? | Eczacıbaşı went public in 1990. |
| Who are competitors of Eczacıbaşı? | Similar companies to Eczacıbaşı include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Eczacıbaşı? | Eczacıbaşı's current market cap is $792M |
| What is the current revenue growth of Eczacıbaşı? | Eczacıbaşı revenue growth between 2023 and 2024 was 35%. |
| Is Eczacıbaşı profitable? | Yes, Eczacıbaşı is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
